NuPathe submits US NDA for transdermal sumatriptan to treat migraine
This article was originally published in Scrip
Executive Summary
NuPathe, a specialty pharmaceutical company in Conshohocken, Pennsylvania, has submitted an NDA to the FDA seeking approval to market its lead product, Zelrix, a transdermal patch delivering sumatriptan via iontophoresis, to treat migraine.